Economics & Markets
Who Actually Controls Access in Value Capture?
Mylan Pharmaceuticals’ EpiPen price hike from $100 to $600 had little to do with innovation — it hinged on a strategic chokehold over access.
2026-07-151 min read
The illusion of value capture is that creating more value automatically secures higher profits. In truth, the determinant is not the value created but the control of access to it. Mylan’s EpiPen case epitomizes this: between 2009 and 2016, the company raised prices for a life-saving allergy treatment by over 500% despite minimal product improvements. The secret wasn’t invention but access control. By hoarding patents, blocking generic competition through legal tactics, and locking out alternative suppliers via exclusive pharmacy contracts, Mylan transformed a medical necessity into a cartel-like monopoly.
This dynamic follows a three-step mechanism: First, patent stacking — securing overlapping patents to block competitors from entering the market. Second, distribution lock-in — ensuring pharmacies and insurers rely on your product through exclusive deals. Third, demand inelasticity — pricing where demand is unavoidable, like life-or-death scenarios. The true profit engine isn’t the value you create but the friction you insert between consumers and alternatives.
Consider the second-order consequence: access control turns into a self-reinforcing loop. Mylan’s pricing pressure incentivized hospitals to stock EpiPens even at inflated costs, and insurers to absorb the expense rather than cover alternative treatments. The product’s actual value (its medical efficacy) became secondary to the control of access.
Key insights
Value capture hinges on access control, not just value creation.
Patent stacking and distribution lock-in create unassailable moats in markets with inelastic demand.
Demand inelasticity is the final lever — price where alternatives are impossible, not just scarce.
Why it matters
Ignoring access control leads to undervaluing your product — even if you create immense value, competitors can undercut you by seizing access points.
Over-reliance on access control without value creation risks backlash, as seen in Mylan’s public relations collapse and congressional scrutiny.
Use this tomorrow
1Audit your business’s access mechanisms. For each product, list three barriers to entry (patents, supplier exclusivity, regulatory hurdles) and rate how strictly they’re enforced.
2Map your competitors’ access points. Identify one friction point they rely on and draft a contingency plan to bypass or neutralize it.
Go deeper
The concept roots in Coase’s transaction cost theory, where control over access points reduces market frictions for the monopolist while inflating them for others. Mylan’s strategy mirrors pharmaceutical industry norms, where companies spend more on patent litigation than R&D in certain sectors, cementing access as the core asset.
The risk is access control decay. When Mylan’s EpiPen patents expired, competitors like Teva Pharmaceutical launched generic versions, splintering the monopoly. Access barriers must evolve: Mylan’s failure to maintain post-patent exclusivity revealed that static defenses crumble under market pressure.
